Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $254.00 to $260.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 34.34% from the company's current price.

ASND has been the topic of several other research reports. Bank of America boosted their price objective on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Wedbush upped their price target on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada upped their price target on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Sixteen research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $243.36.

Ascendis Pharma A/S Stock Down 0.3%

Shares of NASDAQ:ASND traded down $0.54 during trading on Tuesday, hitting $193.55. 65,787 shares of the company were exchanged, compared to its average volume of 492,982. The business's 50 day moving average is $176.43 and its 200-day moving average is $162.07. The company has a market capitalization of $11.84 billion, a P/E ratio of -37.51 and a beta of 0.41. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASND. LPL Financial LLC increased its stake in shares of Ascendis Pharma A/S by 60.1% during the 4th quarter. LPL Financial LLC now owns 4,199 shares of the biotechnology company's stock worth $578,000 after purchasing an additional 1,577 shares during the last quarter. Geode Capital Management LLC grew its stake in Ascendis Pharma A/S by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company's stock valued at $7,858,000 after buying an additional 629 shares in the last quarter. Legal & General Group Plc grew its stake in Ascendis Pharma A/S by 1,577.6% in the 4th quarter. Legal & General Group Plc now owns 17,682 shares of the biotechnology company's stock valued at $2,433,000 after buying an additional 16,628 shares in the last quarter. Mariner LLC grew its stake in Ascendis Pharma A/S by 31.0% in the 4th quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock valued at $297,000 after buying an additional 511 shares in the last quarter. Finally, Guggenheim Capital LLC grew its stake in Ascendis Pharma A/S by 256.9% in the 4th quarter. Guggenheim Capital LLC now owns 7,249 shares of the biotechnology company's stock valued at $998,000 after buying an additional 5,218 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.